Developmental Funds

发展基金

基本信息

  • 批准号:
    10625759
  • 负责人:
  • 金额:
    $ 30.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

DEVELOPMENTAL FUNDS: ABSTRACT Cancer Center Support Grant (CCSG) Developmental Funds are critical to fulfill the mission of the University of Florida Health Cancer Center (UFHCC). Developmental Funds foster innovative research and strategic recruitment aligned with the Center's strategic initiatives. Since 2016, the UFHCC has collaborated across the University of Florida in the internal and external recruitment of 58 new UFHCC members (45 new to UF), of which 39 (67%) are early-stage investigators (ESIs), 26 (45%) are women, and 10 (17%) are underrepresented minorities. Faculty were recruited into 8 of the colleges that contribute members to the UFHCC. Of these recruits, 20 are members of Mechanisms of Oncogenesis, 19 are members of Cancer Therapeutics and Host Response, and 19 are in Cancer Control and Population Sciences, showing even distribution across the programs. UFHCC committed a total of $29.9M in start-up support for all recruitment, with $14.4M expended to date. These new UFHCC members have already made significant contributions to the center in terms of collaborative programmatic and multi-institutional research, publications, and interventional clinical trials. Importantly, since joining UF, these new members have obtained 56 new peer-reviewed extramural grants totaling $39M (direct costs), of which $14.8M (~38%) is from NCI. The total extramural funding, including transferred grants, attributed to these recruits is $52.4M (direct costs), with $24.2M (46%) awarded by the NCI. The return on investment on UFHCC recruitment expenses to date relative to all extramural peer-reviewed funding (direct costs) attributed to recruits is >3.6:1. Since 2016, the UFHCC Pilot and Exploratory Study Proposals received 183 proposals for review, with 33% approved for funding. Outcomes of projects awarded between 2016 and 2020, for which enough time had passed to assess impact ($3M of pilot funding), included 159 publications and $20M (direct costs, for all award years) in new extramural peer-reviewed funding, a return on investment ratio of ~6.7:1. Since 2016, Developmental Funds have assisted in the expansion of the UFHCC funding portfolio. With the new recruits, total cancer-relevant funding increased from $21M in 2016 to $32.6M in 2021 (up 55%) direct costs, NCI funding increasing from $9.6M to $13.2M (up 37%) direct costs. The overall research productivity of the UFHCC increased from 369 publications in 2016 to 641 in 2021 (up 1.7-fold). The number of publications with impact ≥10 went from 59 in 2016 to 95 in 2021. Since 2016, Developmental Funds also supported the recruitment of 18 members who developed novel interventional IITs. In 2016, accruals to IITs accounted for 70% of participants enrolled in trials (23% of treatment accruals). In 2021, IIT accruals accounted for 91% of enrollments (59% of treatment). Interventional trial accruals increased from 515 in 2016 to 1,748 in 2021 (up 3.4-fold). Treatment accruals increased from 138 in 2016 to 299 in 2021 (up 2.2-fold). Developmental funds will be used for pilot grants to encourage innovative transdisciplinary science on cancers relevant to the catchment area, and recruitment of highly qualified and diverse new members across the 3 research programs.
医疗基金:摘要 癌症中心支持补助金(CCSG)发展基金是至关重要的,以履行大学的使命。 佛罗里达健康癌症中心(UFHCC)。发展基金促进创新研究和战略 招聘符合中心的战略举措。自2016年以来,UFHCC在全球范围内开展合作, 佛罗里达大学在内部和外部招聘58个新的UFHCC成员(45个新的UF), 其中39人(67%)是早期研究者(ESI),26人(45%)是女性,10人(17%)代表性不足 少数群体教师被招募到8个学院,为UFHCC贡献成员。在这些新兵中, 20人是肿瘤发生机制的成员,19人是癌症治疗和宿主反应的成员, 19个是癌症控制和人口科学,显示出在各个项目中的平均分布。UFHCC 承诺为所有招聘提供总计2990万美元的启动支持,迄今已支出1440万美元。这些新 UFHCC成员已经在合作方面为中心做出了重大贡献 项目和多机构研究、出版物和干预性临床试验。重要的是,由于 加入UF,这些新成员已经获得了56个新的同行评审的校外赠款总额为3900万美元(直接 成本),其中1480万美元(约38%)来自NCI。总的校外资金,包括转移赠款,归因于 这些新兵的直接费用为5240万美元,其中2420万美元(46%)由NCI提供。投资回报率 迄今为止,与所有校外同行审查资金(直接费用)相比, 招募比例>3.6:1。自2016年以来,UFHCC试点和探索性研究提案收到了183份提案, 审查,33%获得批准的资金。2016年至2020年授予的项目成果,其中 已经有足够的时间来评估影响(300万美元的试点资金),包括159份出版物和2000万美元(直接 成本,所有获奖年份)在新的校外同行评审的资金,投资回报率约为6.7:1。以来 2016年,发展基金协助扩大了UFHCC的资金组合。与新 招募,癌症相关资金总额从2016年的2100万美元增加到2021年的3260万美元(增长55%)直接成本, NCI资金从960万美元增加到1320万美元(增长37%)。整体研究生产力的 UFHCC从2016年的369篇增加到2021年的641篇(增长1. 7倍)。出版物的数量 影响≥10从2016年的59人增加到2021年的95人。自2016年以来,发展基金也支持招聘 18名开发新型干预性IIT的成员。2016年,IIT应计费用占 参加试验的受试者(占治疗累积的23%)。2021年,个人所得税应计项目占入学人数的91% (59%的治疗)。干预性试验应计项目从2016年的515项增加到2021年的1,748项(增长3. 4倍)。 治疗累计数从2016年的138项增加到2021年的299项(增长2. 2倍)。发展资金将用于 提供试点赠款,以鼓励与集水区有关的创新跨学科癌症科学,以及 在3个研究项目中招募高素质和多样化的新成员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan D. Licht其他文献

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl
肿瘤抑制因子 BRCA1 对细胞周期的抑制需要 CDK 抑制剂 p21WAF1/CiP1
  • DOI:
    10.1038/38291
  • 发表时间:
    1997-09-11
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Kumaravel Somasundaram;Hongbing Zhang;Yi-Xin Zeng;Yariv Houvras;Yi Peng;Hongxiang Zhang;Gen Sheng Wu;Jonathan D. Licht;Barbara L. Weber;Wafik S. El-Deiry
  • 通讯作者:
    Wafik S. El-Deiry
HLA-DR, CD33<sup>+</sup>, CD56<sup>+</sup>, CD16<sup>-</sup> Myeloid/Natural Killer Cell Acute Leukemia: A Previously Unrecognized Form of Acute Leukemia Potentially Misdiagnosed as French-American-British Acute Myeloid Leukemia-M3
  • DOI:
    10.1182/blood.v84.1.244.244
  • 发表时间:
    1994-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Amy A. Scott;David R. Head;Kenneth J. Kopecky;Frederick R. Appelbaum;Karl S. Theil;Michael R. Grever;l-Ming Chen;Michael H. Whittaker;Barbara B. Griffith;Jonathan D. Licht;Samuel Waxman;Margaret M. Whalen;Arthur D. Bankhurst;Lynn C. Richter;Thomas M. Grogan;Cheryl L. Willman
  • 通讯作者:
    Cheryl L. Willman
Compound Loss of <em>Dnmt3a</em> and <em>Kmt2c</em> in Myeloid Malignancies
  • DOI:
    10.1182/blood-2023-189411
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Prabhjot Kaur;Cassandra Berntsen;James Leonard;Daniil Shabashvili;Qingchen Yuan;Bowen Yan;Richard Lynn Bennett;Alberto Riva;Jonathan D. Licht;Olga A. Guryanova
  • 通讯作者:
    Olga A. Guryanova
Synergistic Effect of Trifluridine and PARPi Combination in Targeting <em>TP53</em>-Mutated AML
  • DOI:
    10.1182/blood-2024-201781
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Phani Krishna Parcha;Vivek M. Shastri;Jonathan D. Licht;Jatinder K. Lamba
  • 通讯作者:
    Jatinder K. Lamba
Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine.
Sprouty1 通过其 N 端酪氨酸控制泌尿生殖系统的发育。
  • DOI:
    10.1681/asn.2018111085
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Vaquero;S. Cuesta;C. Anerillas;Gisela Altés;J. Ribera;M. Albert Basson;Jonathan D. Licht;J. Egea;M. Encinas
  • 通讯作者:
    M. Encinas

Jonathan D. Licht的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan D. Licht', 18)}}的其他基金

Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
探索 T 细胞急性淋巴细胞白血病中的 microRNA 降解
  • 批准号:
    10717486
  • 财政年份:
    2023
  • 资助金额:
    $ 30.5万
  • 项目类别:
UF Health Cancer Center Support Grant - Training Navigator Supplement
佛罗里达大学健康癌症中心支持补助金 - 培训导航补充
  • 批准号:
    10892335
  • 财政年份:
    2023
  • 资助金额:
    $ 30.5万
  • 项目类别:
University of Florida Health Cancer Center Support Grant
佛罗里达大学健康癌症中心支持补助金
  • 批准号:
    10625750
  • 财政年份:
    2023
  • 资助金额:
    $ 30.5万
  • 项目类别:
Leadership, Planning, and Evaluation
领导、规划和评估
  • 批准号:
    10625761
  • 财政年份:
    2023
  • 资助金额:
    $ 30.5万
  • 项目类别:
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
定义和针对黑色素瘤中表观遗传可塑性驱动的耐药性和免疫逃逸
  • 批准号:
    10666665
  • 财政年份:
    2022
  • 资助金额:
    $ 30.5万
  • 项目类别:
KDM6A mutation as an epigenetic driver of multiple myeloma
KDM6A 突变作为多发性骨髓瘤的表观遗传驱动因素
  • 批准号:
    10229675
  • 财政年份:
    2020
  • 资助金额:
    $ 30.5万
  • 项目类别:
2019 Cancer Genetics and Epigenetics GRC/GRS
2019年癌症遗传学和表观遗传学GRC/GRS
  • 批准号:
    9754282
  • 财政年份:
    2019
  • 资助金额:
    $ 30.5万
  • 项目类别:
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
MMSET 在淋巴恶性肿瘤发病机制和进展中的作用
  • 批准号:
    9330809
  • 财政年份:
    2016
  • 资助金额:
    $ 30.5万
  • 项目类别:
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
MMSET 在淋巴恶性肿瘤发病机制和进展中的作用
  • 批准号:
    9759647
  • 财政年份:
    2016
  • 资助金额:
    $ 30.5万
  • 项目类别:
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer
癌症中染色质的时空组织和信息传递
  • 批准号:
    8866966
  • 财政年份:
    2015
  • 资助金额:
    $ 30.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了